Synlab AG
XETRA:SYAB
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
9.8119
12.0279
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Synlab AG
Synlab AG
Total Liabilities & Equity
Synlab AG
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Synlab AG
XETRA:SYAB
|
Total Liabilities & Equity
€4.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
Total Liabilities & Equity
€33.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
7%
|
|
|
Fresenius SE & Co KGaA
XETRA:FRE
|
Total Liabilities & Equity
€42.4B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
1%
|
|
|
Vita 34 AG
XETRA:V3V
|
Total Liabilities & Equity
€157.6m
|
CAGR 3-Years
39%
|
CAGR 5-Years
21%
|
CAGR 10-Years
16%
|
|
|
E
|
Euroeyes International Eye Clinic Ltd
HKEX:1846
|
Total Liabilities & Equity
HK$1.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
26%
|
CAGR 10-Years
N/A
|
|
|
Fresenius Medical Care AG
XMUN:FME
|
Total Liabilities & Equity
€33.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
7%
|
|
Synlab AG
Glance View
Synlab AG is a clinical laboratory and medical diagnostic services company. The company is headquartered in Muenchen, Bayern and currently employs 27,337 full-time employees. The firm is engaged in laboratory services for human and veterinary medicine, as well as environmental analysis.
See Also
What is Synlab AG's Total Liabilities & Equity?
Total Liabilities & Equity
4.7B
EUR
Based on the financial report for Dec 31, 2023, Synlab AG's Total Liabilities & Equity amounts to 4.7B EUR.
What is Synlab AG's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 3Y
-4%
Over the last year, the Total Liabilities & Equity growth was -13%. The average annual Total Liabilities & Equity growth rates for Synlab AG have been -4% over the past three years .
You don't have any saved screeners yet
